Vaccinia virus, a promising new therapeutic agent for pancreatic cancer

Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers

(2015) Neha Singh et al.   DRUG DISCOVERY TODAY

Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model

(2015) J Poutou et al.   GENE THERAPY

Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus

(2015) J Hughes et al.   GENE THERAPY

Viruses for Tumor Therapy

(2014) John Bell et al.   Cell Host & Microbe

A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer

(2014) L. S. Chard et al.   CLINICAL CANCER RESEARCH

IL-10: The Master Regulator of Immunity to Infection

(2014) Kevin N. Couper et al.   JOURNAL OF IMMUNOLOGY

CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy

(2014) Christine E Engeland et al.   MOLECULAR THERAPY

Human Vaccines & Immunotherapeutics: News

(2014) Eva M. Riedmann   Human Vaccines & Immunotherapeutics

Oncolytic vaccinia virus in combination with radiation shows synergistic antitumor efficacy in pancreatic cancer

(2013) M.H. Dai et al.   CANCER LETTERS

Oncolytic viruses as therapeutic cancer vaccines

(2013) David L Bartlett et al.   Molecular Cancer

Vaccinia Virus Induces Programmed Necrosis in Ovarian Cancer Cells

(2013) Lynsey M Whilding et al.   MOLECULAR THERAPY

Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients

(2013) Ilkka Liikanen et al.   MOLECULAR THERAPY

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

(2013) Jeong Heo et al.   NATURE MEDICINE

Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated Complement-Dependent Cancer Cell Lysis in Humans

(2013) M. K. Kim et al.   Science Translational Medicine

Reflections on the early development of poxvirus vectors

(2013) Bernard Moss   VACCINE

A Novel Genetically Modified Oncolytic Vaccinia Virus in Experimental Models is Effective Against a Wide Range of Human Cancers

(2012) Dana Haddad et al.   ANNALS OF SURGICAL ONCOLOGY

Oncolytic Virus and Anti-4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer

(2012) L. B. John et al.   CANCER RESEARCH

Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus

(2012) I. Diaconu et al.   CANCER RESEARCH

Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

(2012) S. Miyamoto et al.   CANCER RESEARCH

A Novel Therapeutic Regimen to Eradicate Established Solid Tumors with an Effective Induction of Tumor-Specific Immunity

(2012) J. R. Tysome et al.   CLINICAL CANCER RESEARCH

Oncolytic Viruses for Induction of Anti-Tumor Immunity

(2012) Alex W. Tong et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Myxoma Virus Sensitizes Cancer Cells to Gemcitabine and Is an Effective Oncolytic Virotherapeutic in Models of Disseminated Pancreatic Cancer

(2012) Sonia Tusell Wennier et al.   MOLECULAR THERAPY

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

(2012) Susanne H. Sheehy et al.   PLoS One

Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-Region

(2012) Enrique Miranda et al.   PLoS One

Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration

(2011) Pyung-Hwan Kim et al.   BIOMATERIALS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models

(2011) G Cherubini et al.   GENE THERAPY

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4

(2011) J D Dias et al.   GENE THERAPY

Measles virus causes immunogenic cell death in human melanoma

(2011) O G Donnelly et al.   GENE THERAPY

Envelope-chimeric Entry-targeted Measles Virus Escapes Neutralization and Achieves Oncolysis

(2011) Tanner S Miest et al.   MOLECULAR THERAPY

MicroRNA Regulation of Glycoprotein B5R in Oncolytic Vaccinia Virus Reduces Viral Pathogenicity Without Impairing Its Antitumor Efficacy

(2011) Mina Hikichi et al.   MOLECULAR THERAPY

Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors

(2011) Susanne H Sheehy et al.   MOLECULAR THERAPY

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers

(2011) Kelley A Parato et al.   MOLECULAR THERAPY

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

(2011) Caroline J. Breitbach et al.   NATURE

Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines

(2010) M.-H. Dai et al.   BRITISH JOURNAL OF SURGERY

A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer

(2010) A Nakao et al.   CANCER GENE THERAPY

Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model

(2010) Hidenobu Ishizaki et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1

(2010) B Huang et al.   GENE THERAPY

Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry

(2010) J. Mercer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles

(2010) Han Hsi Wong et al.   Viruses-Basel

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY

Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma

(2009) K F D Kuhlmann et al.   CANCER GENE THERAPY

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

(2009) Thomas J. Scriba et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours

(2009) C T Hiley et al.   GENE THERAPY

Lister strain of vaccinia virus armed with endostatin–angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer

(2009) J R Tysome et al.   GENE THERAPY

Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice

(2009) Hanh K. Le et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68

(2009) Y. A. Yu et al.   MOLECULAR CANCER THERAPEUTICS

Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands

(2009) Roman Barbalat et al.   NATURE IMMUNOLOGY

Viruses as vaccine vectors for infectious diseases and cancer

(2009) Simon J. Draper et al.   NATURE REVIEWS MICROBIOLOGY

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome

(2009) Julie Delaloye et al.   PLoS Pathogens

Enhancing Poxvirus Oncolytic Effects through Increased Spread and Immune Evasion

(2008) D. H. Kirn et al.   CANCER RESEARCH

Cell Surface Expression of the Vaccinia Virus Complement Control Protein Is Mediated by Interaction with the Viral A56 Protein and Protects Infected Cells from Complement Attack

(2008) N. M. Girgis et al.   JOURNAL OF VIROLOGY

The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma

(2008) Ta-Chiang Liu et al.   MOLECULAR THERAPY

Effective induction of high-titer antibodies by viral vector vaccines

(2008) Simon J Draper et al.   NATURE MEDICINE